CRISPR Therapeutics, a preclinical biotech developing therapies based on CRISPR/Cas9 gene editing, raised $56 million by offering 4 million shares at $14, below the range of $15 to $17. CRISPR Therapeutics plans to list on the Nasdaq under the symbol CRSP. Citi, Piper Jaffray and Barclays acted as lead managers on the deal.
